Virtual twin approach using physiologically based pharmacokinetic modelling in hospitalized patients treated with apixaban or rivaroxaban
In a large cohort of hospitalized patients, a PBPK model incorporating demographic characteristics and kidney function can accurately predict, within bioequivalency criteria, an individual's apixaban and rivaroxaban plasma exposure. The added value of individual Pgp and 3A phenotypes on the predictive performance need to be further explored, although patients at higher risk for bleeding may benefit. This innovative approach represents an important step towards the application of PBPK at bedside.
Authors
- Victoria Rollason (ORCID: https://orcid.org/0000-0002-8073-6610)
- Caroline Samer (ORCID: https://orcid.org/0000-0001-8178-0616)
- Camille Lenoir (ORCID: https://orcid.org/0000-0001-6506-8629)
- Pauline Gosselin
- Chantal Csajka (ORCID: https://orcid.org/0000-0002-0660-082X)
- Youssef Daali (ORCID: https://orcid.org/0000-0002-8391-9383)
- Jean‐Luc Reny (ORCID: https://orcid.org/0000-0002-7528-7363)
- Pierre Fontana (ORCID: https://orcid.org/0000-0003-1546-0774)
- Jean E. Terrier (ORCID: https://orcid.org/0000-0002-5878-4878)
- Frédéric Gaspar (ORCID: https://orcid.org/0000-0002-0225-7294)
- Celestin Jacot‐Descombes
- Valentine Ardoino
Institutions
- University of Geneva (CH)
- HES-SO University of Applied Sciences and Arts Western Switzerland (CH)
- University Hospital of Geneva (CH)
- University of Lausanne (CH)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1002/bcp.70032
- Citations
- 4
- Primary Topic
- Cardiac electrophysiology and arrhythmias
- Type
- article
- Field-Weighted Citation Impact
- 5.55
Funders
- Hôpitaux Universitaires de Genève